TLDR:
- Canaan, a venture capital firm, has added former Pfizer executive Uwe Schoenbeck to its healthcare investment team
- Dr. Schoenbeck will be joining as a new venture partner and will have an additional $100 million to draw from as the firm expands its biopharma investment funds
Californian venture capital firm Canaan has added former Pfizer senior executive Uwe Schoenbeck to its healthcare investment team. Dr. Schoenbeck will be joining as a new venture partner, bringing with him a wealth of experience from his time at Pfizer. In addition to his role, he will also have an additional $100 million to draw from, as Canaan announced the expansion of its biopharma investment funds. Canaan had raised $850 million for the Canaan XIII fund in April 2023, aimed at supporting visionary projects in the healthcare industry.
This move is expected to bolster Canaan’s presence in the biopharma investment space and leverage Dr. Schoenbeck’s expertise to identify and support innovative healthcare startups. With this new appointment and expansion of investment funds, Canaan is poised to make significant strides in the biopharma sector in the coming years.
